drugset / Trial / NCT00006113
Vaccine Therapy Followed by Biological Therapy in Treating Patients With Stage III or Stage IV Melanoma
Phase 2
Terminated
25 enrolled
University of Southern California
National Cancer Institute (NCI) · collab
Treatment
Summary
RATIONALE: Vaccines made from melanoma cells may make the body build an immune response to kill tumor cells. Biological therapies such as interferon gamma and interleukin-2 use different ways to stimulate the immune system and stop cancer cells from growing. Combining vaccine therapy with biological therapy may kill more tumor cells. PURPOSE: This phase II trial is studying giving vaccine therapy together with interferon gamma and interleukin-2 in treating patients with stage III or stage IV melanoma.
Timeline
- Start
- 1999-06
- Primary completion
- 2003-05
- Completion
- 2006-04
Outcome
Outcome not reported
Stopped: “Lack of efficacy”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MART-1 | Peptide | — | — |
| Subject | aldesleukin | Protein / enzyme biologic | — | Subcutaneous |
| Subject | autologous dendritic cells | Cell therapy | — | — |
| Subject | gp100 | Vaccine | — | — |
| Subject | tyrosinase peptide | Peptide | — | — |
| Background | CD40-ligand | Protein / enzyme biologic | — | — |
| Background | Interleukin-4 | Protein / enzyme biologic | — | — |
| Background | Tumor Infiltrating Lymphocytes | Cell therapy | — | — |
| Background | interferon gamma | Protein / enzyme biologic | — | — |
| Background | sargramostim | Protein / enzyme biologic | — | — |